Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01703065 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib in Men With Castration-Resistant Prostate Cancer
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01703065 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 9 participants.
The verdict
NCT01703065, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-06-18 |
| Est. Completion | 2015-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01703065
The ClinicalTrials.gov registry entry for NCT01703065 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cabozantinib is the first listed.
NCT01703065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01703065 about?
NCT01703065 is a clinical study titled "Cabozantinib in Men With Castration-Resistant Prostate Cancer". This pilot clinical trial studies cabozantinib in treating men with castration-resistant prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01703065?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2013-06-18. Estimated completion is 2015-09-18.
What interventions are being tested in trial NCT01703065?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT01703065?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.